XML 42 R5.htm IDEA: XBRL DOCUMENT v2.4.0.6
Consolidated Statement of Stockholders' Equity (USD $)
Total
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Accumulated Other Comprehensive Income (Loss)
Beginning balance at Dec. 31, 2008 $ 21,808,985 $ 949,455 $ 279,868,802 $ (259,001,524) $ (7,748)
Beginning balance, shares at Dec. 31, 2008   9,494,560      
Comprehensive loss          
Net loss (27,026,411)     (27,026,411)  
Unrealized gain (loss) on foreign currency translation 272,184       272,184
Change in unrealized gain (loss) on securities available-for-sale 130,287       130,287
Comprehensive loss (26,623,940)        
Issuance of common stock and warrants, net of issuance cost of $1,351,487 and $1,522,083 in 2009 and 2011 respectively, shares   1,981,740      
Issuance of common stock and warrants, net of issuance cost of $1,351,487 and $1,522,083 in 2009 and 2011 respectively 26,467,314 198,174 26,269,140    
Common stock issued for acquisition of SCS, shares   265,000      
Common stock issued for acquisition of SCS 4,425,500 26,500 4,399,000    
Common stock issued for licensing agreements, shares 590 590      
Common stock issued for licensing agreements 10,000 59 9,941    
Common stock issued pursuant to employee benefit plan, shares   9,848      
Common stock issued pursuant to employee benefit plan 156,932 985 155,947    
Compensation expense from grant of options, restricted stock units and stock (fair value) 4,046,339   4,046,339    
Exercise of employee and director stock options, shares   31,528      
Exercise of employee and director stock options 252,984 3,152 249,832    
Exercise and net settlement of restricted stock units, shares   34,245      
Exercise and net settlement of restricted stock units (380,548) 3,425 (383,973)    
Exercise of warrants, shares   17,447      
Exercise of warrants 331,501 1,745 329,756    
Ending balance at Dec. 31, 2009 30,495,067 1,183,495 314,944,784 (286,027,935) 394,723
Ending balance, shares at Dec. 31, 2009   11,834,958      
Comprehensive loss          
Net loss (25,243,551)     (25,243,551)  
Unrealized gain (loss) on foreign currency translation (268,810)       (268,810)
Change in unrealized gain (loss) on securities available-for-sale (6,191)       (6,191)
Comprehensive loss (25,518,552)        
Issuance of common stock, net of issuance cost of $480,835, shares   847,520      
Issuance of common stock, net of issuance cost of $480,835 7,279,234 84,752 7,194,482    
Common stock issued pursuant to employee benefit plan, shares   18,488      
Common stock issued pursuant to employee benefit plan 232,229 1,849 230,380    
Compensation expense from grant of options, restricted stock units and stock (fair value) 3,697,405   3,697,405    
Exercise of employee and director stock options, shares   3,451      
Exercise of employee and director stock options 19,802 345 19,457    
Exercise and net settlement of restricted stock units, shares   53,370      
Exercise and net settlement of restricted stock units (483,406) 5,337 (488,743)    
Stock retired from settlement agreement, shares   (26,500)      
Stock retired from settlement agreement (241,150) [1] (2,650) (238,500)    
Ending balance at Dec. 31, 2010 15,480,629 1,273,128 325,359,265 (311,271,486) 119,722
Ending balance, shares at Dec. 31, 2010   12,731,287      
Comprehensive loss          
Net loss (21,328,536)     (21,328,536)  
Unrealized gain (loss) on foreign currency translation 40,032       40,032
Change in unrealized gain (loss) on securities available-for-sale (119,041)       (119,041)
Comprehensive loss (21,407,545)        
Issuance of common stock and warrants, net of issuance cost of $1,351,487 and $1,522,083 in 2009 and 2011 respectively, shares   9,525,116      
Issuance of common stock and warrants, net of issuance cost of $1,351,487 and $1,522,083 in 2009 and 2011 respectively 13,792,340 187,779 13,604,561    
Common stock issued pursuant to employee benefit plan, shares   35,164      
Common stock issued pursuant to employee benefit plan 164,896 1,327 163,569    
Compensation expense from grant of options, restricted stock units and common stock (fair value), shares   32,631      
Compensation expense from grant of options, restricted stock units and stock (fair value) 3,096,043 1,267 3,094,776    
Exercise of employee and director stock options, shares   1,692      
Exercise of employee and director stock options 2,386 169 2,217    
Exercise and net settlement of restricted stock units, shares   102,065      
Exercise and net settlement of restricted stock units (403,625) 9,106 (412,731)    
Ending balance at Dec. 31, 2011 $ 10,725,124 $ 1,472,776 $ 341,811,657 $ (332,600,022) $ 40,713
Ending balance, shares at Dec. 31, 2011   22,427,955      
[1] On April 1, 2009, we acquired the operations of Stem Cell Sciences Plc (SCS, which subsequently changed its name to Asset Realisation Company Limited). As consideration, we issued 265,000 shares of our common stock with a closing price of $16.70 per share and waived certain commitments of SCS to repay approximately $709,000 in principal and accrued interest owed to us. Pursuant to the acquisition agreement, 20% of the 265,000 shares were placed into an escrow for a twelve month period to satisfy any indemnification obligations owed to us by SCS. On August 19, 2010, we entered into a settlement agreement with SCS in which the parties agreed to the release of half the escrowed shares to SCS and half to us in full satisfaction of our claims for indemnification, and both parties waived all other claims, known and unknown, against the other. The 26,500 shares returned to us are being treated as retired and no longer outstanding. We have recorded approximately $227,000 as other income, which was the value of these shares based on the closing price of $9.10 per share on August 19, 2010, and net of amounts already accrued for potential claims against the escrowed shares.